BioSpace News Archive

Biotech Bay

Varian Selected to Equip Two Proton Therapy Centers in Norway

Following a comprehensive evaluation by Sykehusbygg HF Norway and regional health authorities, Varian was selected to equip two proton therapy centers in Norway with the ProBeam® multi-room system.

May 9, 2019
·
2 min read
Altavant Sciences to Provide Corporate and Clinical Update at 2019 Respiratory Innovation Summit

Altavant Sciences announced that it has been invited to present at the 2019 Respiratory Innovation Summit being held May 17 in Dallas, TX.

May 9, 2019
·
2 min read
Business

QOL Medical, LLC Partners with the GI Health Foundation for an Investigative Health Series on CSID and IBS-D, Featuring William D. Chey, MD, One of the Nation’s Most Respected Gastroenterologists

QOL Medical, LLC announced they are partnering with the GI Health Foundation, along with renowned gastroenterologist William D. Chey, MD

May 9, 2019
·
2 min read
Business

Camurus Interim Report January-March 2019

Initial sales of Buvidal® follows plan and we are expecting to see significant growth during the year

May 9, 2019
·
7 min read
Deals

Gossamer Bio to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 14, 2019

Gossamer Bio, Inc. announced that it will report its first quarter 2019 financial results on Tuesday, May 14, 2019.

May 9, 2019
·
1 min read
Deals

Kala Pharmaceuticals Reports First Quarter 2019 Financial Results

Kala Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2019.

May 9, 2019
·
11 min read
Deals

AVEO Reports First Quarter 2019 Financial Results and Provides Business Update

AVEO Oncology reported financial results for the first quarter ended March 31, 2019 and provided a business update.

May 9, 2019
·
14 min read
Deals

Aerpio Reports First Quarter 2019 Financial Results and Provides Business Update

On Track to Initiate Phase 1b Clinical Trial of Topical Drop Formulation of AKB-9778 for Primary Open-Angle Glaucoma (POAG) in the Second Quarter of 2019

May 9, 2019
·
6 min read
Drug Development

Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

Bristol-Myers Squibb Company announced the Phase 3 CheckMate -498 trial evaluating Opdivo plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase-unmethylated glioblastoma multiforme did not meet its primary endpoint of overall survival at final analysis.

May 9, 2019
·
33 min read
FDA

U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

An additional treatment modality would provide more flexibility in how patients receive vedolizumab, a biologic with a gut-selective mode of action

May 9, 2019
·
14 min read